Boston Scientific gets CE Mark for Liberte

Interventional device developer Boston Scientific of Natick, MA, has received the European CE Mark for its Liberte coronary stent.

Liberte will serve as the platform for the company’s next generation of drug-eluting stent systems, Boston Scientific said. The firm will launch the stent in Europe and other international markets, and said it plans to introduce Liberte to the U.S. market in the second half of 2004.

By staff writers
December 30, 2003

Related Reading

Grissom named as Boston Scientific VP, December 10, 2003

Boston Scientific gets panel nod for Taxus, November 21, 2003

Biophan joins forces with Boston Scientific, November 5, 2003

Boston Scientific adds to Rubicon investment, October 30, 2003

Q3 gains reported at Boston Scientific, October 22, 2003

Copyright © 2003

Page 1 of 374
Next Page